Accueil/Actions/IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

Prix en Temps Réel

Healthcare

Drug Manufacturers - Specialty & Generic

Australie

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.344

Haut

$0.349

Bas

$0.336

Volume

15.84M

Fondamentaux de l'Entreprise

Capitalisation Boursière

118.0M

Industrie

Drug Manufacturers - Specialty & Generic

Pays

Australia

Statistiques de Trading

Volume Moyen

66.44M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.08Actuel $0.339Haut $3.12

Actualités Connexes

26 août 2025 · 12:00

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

22 août 2025 · 12:00

GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

8 août 2025 · 12:00

GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical